Full-Time
Posted on 7/9/2024
Develops targeted radiation therapies for cancer
No salary listed
Senior
Remote in USA
Upload your resume to see how it matches 5 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their approach helps healthcare providers make better treatment decisions and offers personalized therapy for patients with significant medical needs. The company focuses on areas like prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a global supply chain to manufacture and distribute its products, generating revenue through sales to healthcare institutions. Unlike many competitors, Telix emphasizes sustainability, patient care, and ethical practices in its operations, aiming to create lasting value for patients, shareholders, and employees.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Melbourne, Australia
Founded
2015
Help us improve and share your feedback! Did you find this helpful?
Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan[1]) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1 study[2]. IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT). The target patient population is patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma. Treatment with TLX101 was well tolerated with no serious adverse events reported. IPAX-Linz demonstrated encouraging preliminary efficacy data, indicating a median overall survival (OS) of 12.4 months from the initiation of treatment with TLX101, or 32.2 months from initial diagnosis[3]
MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ - Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.
Telix today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 2025[1].
Telix holds the exclusive worldwide rights to develop and commercialize radiolabelled forms of olaratumab, which was originally developed by Eli Lilly and Company (Lilly).
Join Telix this week at the 40th Annual European Association of Urology Congress (EAU25) being held in Madrid, Spain.